<DOC>
	<DOCNO>NCT00415818</DOCNO>
	<brief_summary>The primary Objective ass efficacy TG4010 combine chemotherapy comparison chemotherapy alone patient advance non small cell lung cancer .</brief_summary>
	<brief_title>Immunotherapy With TG4010 Patients With Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>In experimental arm patient receive subcutaneous injection TG4010 dose 108 pfu combination chemotherapy treatment whereas patient control arm receive chemotherapy alone . The chemotherapy associate cisplatin gemcitabine give 6 cycle progressive disease , whichever occur first . TG4010 administer per week 6 week , every 3 week combination chemotherapy thereafter monotherapy documentation progressive disease . Tumor response evaluate every 6 week CT-scan result available start additional treatment period 6 week . The tumor response take account patient best overall response obtain study . The endpoint study base Progression Free Survival ( PFS ) 6 month .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Histologically confirm nonsmall cell carcinoma lung ( adenocarcinoma , squamous cell carcinoma , large cell carcinoma ) ; Histological documentation MUC1 antigen expression primary tumor metastasis , define positive stain immunohistochemistry least 25 % tumor cell condition describe technical documentation monoclonal antibody ; Patients stage IIIb `` wet '' ( pleural pericardial effusion ) IV disease , prior systemic therapy advance disease except adjuvant treatment . Prior surgery radiation therapy aim local palliation attempt local disease control permit ; At least one measurable lesion Computed Tomography ( CTscanner ) accord WHO criteria ( lesion accurately measure two dimension longest diameter equal great 10 mm spiral CT scan ) ; Adequate hematological , hepatic , renal function : Hemoglobin &gt; = 10.0 g/dL ; WBC &gt; = 3.0x10e9/L include neutrophil &gt; = 1.5x10e9/L total lymphocyte count &gt; = 0.5x10e9/L ; platelet count &gt; = 100x10e9/L ; Bilirubin = &lt; 2x upper limit normal serum transaminase = &lt; 3x upper limit normal ; Glomerular Filtration Rate high 60 ml/mn accord Cockcroft formula ; Performance status 0 1 ECOG scale ( Appendix 2 ) ; Minimum estimate life expectancy 4 month ; Written inform consent patient . Concomitant brain metastasis . If previous brain metastasis treat , absence evolution demonstrate MRI scanner perform baseline ; Prior history malignancy except basal cell carcinoma intraepithelial cervical cancer cancer complete response since least 5 year ; History form systemic therapy advance nonsmall cell cancer lung except ( neo ) adjuvant treatment ; Previous ( within 4 week prior day 1 ) concomitant long term treatment systemic steroid , immunosuppressive / immunomodulating drug ( e.g . Cyclosporine , cortico√Øds ) ; Positive serology HIV HCV ; positive antigen hepatitis B ; Serious concomitant medical disorder ; Major surgery within 4 week prior day 1 ; Patient organ allograft ; Allergy egg ; Participation another experimental protocol study period , within 4 week prior day 1 ; Pregnancy entry woman breast feeding ; Patient without adequate protection pregnancy conduct study 3 month last injection TG4010 and/or chemotherapy ; History substance abuse ; Patient unable unwilling comply protocol requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Lung Cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Cancer Vaccine</keyword>
	<keyword>Stage IV Non-Small Cell Lung Cancer</keyword>
	<keyword>Stage IIIb Non-Small Cell Lung Cancer effusion</keyword>
</DOC>